Capricor Therapeutics (NASDAQ:CAPR) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR - Free Report) in a research report sent to investors on Thursday,Benzinga reports. They currently have a $77.00 price target on the biotechnology company's stock.

Other research analysts also recently issued reports about the company. Piper Sandler started coverage on Capricor Therapeutics in a research report on Monday, October 21st. They set an "overweight" rating and a $35.00 price objective for the company. Maxim Group upped their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research note on Wednesday, September 25th. Cantor Fitzgerald lifted their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a research note on Thursday, November 14th. Finally, Oppenheimer reiterated an "outperform" rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $34.50.

Capricor Therapeutics Stock Up 8.4 %

Shares of NASDAQ CAPR traded up $1.16 during midday trading on Thursday, hitting $14.96. The company had a trading volume of 1,252,323 shares, compared to its average volume of 1,189,616. The firm has a market capitalization of $680.23 million, a price-to-earnings ratio of -14.11 and a beta of 3.98. Capricor Therapeutics has a twelve month low of $3.52 and a twelve month high of $23.40. The business has a 50-day simple moving average of $16.82 and a two-hundred day simple moving average of $10.81.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. State Street Corp lifted its position in shares of Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company's stock valued at $7,792,000 after acquiring an additional 111,291 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Capricor Therapeutics in the 3rd quarter worth approximately $3,806,000. PFM Health Sciences LP acquired a new stake in Capricor Therapeutics during the 3rd quarter valued at $2,324,000. Renaissance Technologies LLC lifted its holdings in shares of Capricor Therapeutics by 158.7% in the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock valued at $656,000 after purchasing an additional 84,350 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Capricor Therapeutics in the second quarter worth $426,000. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.